Galvus Met 50/500: Indications, Pancreas Protection & Liver Monitoring
Comprehensive guide to Galvus Met (Vildagliptin + Metformin): DPP-4 incretin stabilization, twice-daily meal schedule, LFT liver monitoring, and...
Galvus Met is a combination of Vildagliptin (50mg) and Metformin (500mg). Vildagliptin blocks the DPP-4 enzyme, extending the action of endogenous GLP-1 to enhance insulin and curb glucagon. Because Vildagliptin has a shorter pharmacodynamic duration than sitagliptin, it is typically taken twice daily with morning and evening meals.
1. Beta-Cell and Alpha-Cell Regulation
Vildagliptin uniquely improves sensitivity of both alpha and beta cells in pancreatic islets, appropriately blunting glucagon secretion during meals while augmenting mealtime insulin.
2. Liver Function Test (LFT) Monitoring Guideline
Vildagliptin carries a clinical recommendation to perform baseline Liver Function Tests (LFTs) prior to initiation, followed by checks at 3-month intervals during the first year, as rare reversible hepatic enzyme elevations can occur.
3. Jan Aushadhi Generic Savings
Branded Galvus Met costs ~₹280 for 10 tablets. Bioequivalent Vildagliptin 50mg + Metformin 500mg tablets at Jan Aushadhi cost just ₹38.00 (86% savings).
Top 8 Essential Indian Medicines: Branded MRP vs. Jan Aushadhi Generic Comparison
Compare average Indian retail MRP of top branded formulations against government-certified PMBJP Jan Aushadhi bioequivalent generic prices and active salts. Verified against official PMBJP formularies, NPPA price caps, and CDSCO regulatory registries.
| Brand Name | Leading Manufacturer | Active Salt Formulation (IP) | Branded MRP | Jan Aushadhi Price | Savings % |
|---|---|---|---|---|---|
| Augmentin 625 Duo | GlaxoSmithKline Pharmaceuticals | Amoxicillin Trihydrate 500mg + Potassium Clavulanate 125mg IP | ₹220.00 | ₹58.00 | 74% |
| Dolo 650 | Micro Labs Ltd | Paracetamol (Acetaminophen) 650mg IP | ₹34.00 | ₹5.50 | 84% |
| Pantocid 40 | Sun Pharmaceutical Industries | Pantoprazole Sodium 40mg IP (Gastro-resistant) | ₹155.00 | ₹8.00 | 95% |
| Azithral 500 | Alembic Pharmaceuticals | Azithromycin Dihydrate 500mg IP | ₹132.00 | ₹24.00 | 82% |
| Glycomet 500 | USV Private Limited | Metformin Hydrochloride 500mg IP | ₹24.00 | ₹4.50 | 81% |
| Shelcal 500 | Torrent Pharmaceuticals | Elemental Calcium 500mg + Cholecalciferol (Vit D3) 250 IU IP | ₹134.00 | ₹16.00 | 88% |
| Telma 40 | Glenmark Pharmaceuticals | Telmisartan 40mg IP | ₹92.00 | ₹7.50 | 92% |
| Montair-LC | Cipla Ltd | Montelukast Sodium 10mg + Levocetirizine Dihydrochloride 5mg IP | ₹210.00 | ₹18.00 | 91% |
| Combined 8-Drug Essential Therapy Basket Total: | ₹1,001.00 | ₹141.00 | 85.9% Net Savings | ||
Frequently Asked Questions (Clinical & Regulatory)
Q1: Can Galvus Met cause weight loss?
Galvus Met is weight-neutral to slightly weight-reducing due to the metformin component and incretin-mediated satiety.
Q2: Is Galvus Met safe for heart failure patients?
Unlike some other DPP-4 inhibitors (like saxagliptin), Vildagliptin has shown a neutral profile regarding heart failure hospitalization risks.
Q3: What makes Metformin Hydrochloride IP the universal first-line therapy in Type 2 Diabetes?
Metformin Hydrochloride (e.g. Glycomet 500) acts primarily by activating AMP-activated protein kinase (AMPK) in hepatocytes, suppressing hepatic gluconeogenesis and enhancing peripheral insulin sensitivity without stimulating pancreatic beta cells or causing weight gain.
Q4: How do PMBJP generic diabetes medicines compare with branded formulations?
Generic Metformin, Glimepiride, and Voglibose formulations at Jan Aushadhi Kendras undergo NABL testing and provide equivalent glycemic control at 80% to 90% cost savings for chronic life-long daily management.
Q5: What is the clinical Rule of 15 for managing acute hypoglycemia?
When blood glucose falls below 70 mg/dL with adrenergic symptoms, consume 15 grams of fast-acting carbohydrate (e.g., 3 glucose tablets, 1/2 cup fruit juice, or 3 teaspoons sugar), wait 15 minutes, and re-check capillary blood glucose. Repeat if readings remain below 70 mg/dL.
This clinical guide is authored and reviewed in accordance with the regulatory standards of the Indian Pharmacopoeia (IP), Central Drugs Standard Control Organization (CDSCO) drug schedules, and Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) bioequivalence guidelines. All therapeutic recommendations and drug interaction warnings are cross-referenced with official statutory publications.
Under India's Digital Personal Data Protection (DPDP) Act, 2023, MediMatch AI functions as a data fiduciary committed to zero retention of private health identifiers. Browsing educational guides, reviewing active salt monographs, and executing search queries occur without tracking or commercial profiling. All client interactions with prescription readers or lab decoders execute ephemerally in volatile memory with zero server-side storage of protected health information (PHI). For inquiries regarding data fiduciary obligations, contact our Data Protection Officer at privacy@medimatchai.in.